Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RN7SL801P is a pseudogene corresponding to the 7SL RNA, which forms the RNA backbone of the signal recognition particle (SRP) ribonucleoprotein complex in cells[1][3]. Pseudogenes are nonfunctional DNA sequences that are similar to functional genes but have lost their gene expression or protein-coding ability, often because of mutations or truncations[2][4][6]. RN7SL801P is not considered a protein, enzyme, receptor, transporter, or drug target. It is one of many 7SL-related pseudogenes found in the human genome, most of which are truncated and formed by reverse transcription events[6]. These sequences do not encode for functional RNA or protein products and have no known therapeutic potential or involvement in disease biology as of current knowledge[1][6]. While the parent molecule 7SL RNA is functionally important as an essential part of the SRP complex, RN7SL801P is a disabled, nonfunctional duplicate (a \"dead\" gene) and not itself a therapeutic or biomarker target[2][6]. There is no evidence or literature establishing RN7SL801P as a receptor, drug target, or disease biomarker, nor are there drugs known to interact with it[1]. Pseudogenes in general, including this one, may sometimes interfere with genetic studies due to sequence similarity to their parent genes[2]. If structured data specific to RN7SL801P's function, roles in disease, drug interactions, etc., becomes available in the future, those entries should be updated. For now, it fits within the pseudogene family, with no direct biological or clinical significance[1][2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 801, pseudogene (RN7SL801P).